Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately ‘to pursue new challenges’. Clark will ‘support [Destiny] for a limited period to ensure an orderly handover.’ Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held ‘key roles’ at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC.
Barker says: ‘The business is well positioned to build on the progress that has been achieved and there are significant opportunities that lie ahead for the company. My primary focus will be on advancing partnership discussions for [experimental drug candidate] XF-73 nasal, and I look forward to leading Destiny until the board appoints a permanent successor to drive the business through its next phase of growth.’
Current stock price: 30.65 pence, down 8.5% in London on Thursday
12-month change: down 31%
Copyright 2023 Alliance News Ltd. All Rights Reserved.